Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket

argenx Completes Acquisition of Forte Biosciences, Inc.

argenx successfully completed its acquisition of Forte Biosciences for $77.00 per share in cash, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The acquisition expands argenx's immunology portfolio and supports its Vision 2030 strategy to become a leading immunology innovation company by targeting diseases with limited treatment options.

argenx shares are trading higher after UBS upgraded its rating on the stock from Neutral to Buy and raised its price target from $960 to $1400. Also, Wells Fargo maintained its Overweight rating and raised its price target from $1350 to $1415.

UBS Upgrades argenx to Buy, Raises Price Target to $1400

Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1415

Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1350 to $1415.

Bio Green Med Solution Q2 EPS $(0.08) Up From $(0.93) YoY, Sales $336.000K

Bio Green Med Solution (NASDAQ:BGMS) reported quarterly losses of $(0.08) per share. This is a 91.4 percent increase over losses of $(0.93) per share from the same period last year. The company reported $336.000

Baiya International Completes Additional $2M Strategic Investments In Binance Coin

Further Advancing the Binance Plan Through Long-Term Capital Allocation While Expanding the Company's Digital Asset PortfolioSHENZHEN, China, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Baiya International Group Inc.